- Home
- ADIL vs SNOA Comparison
ADIL vs SNOA Comparison
Compare ADIL & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- SNOA
- Stock Information
- Founded
- ADIL 2010
- SNOA 1999
- Country
- ADIL United States
- SNOA United States
- Employees
- ADIL N/A
- SNOA N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- SNOA Health Care
- Exchange
- ADIL Nasdaq
- SNOA Nasdaq
- Market Cap
- ADIL 7.7M
- SNOA 7.5M
- IPO Year
- ADIL 2018
- SNOA 2007
- Fundamental
- Price
- ADIL $0.40
- SNOA $4.17
- Analyst Decision
- ADIL Strong Buy
- SNOA
- Analyst Count
- ADIL 2
- SNOA 0
- Target Price
- ADIL $4.75
- SNOA N/A
- AVG Volume (30 Days)
- ADIL 745.4K
- SNOA 63.2K
- Earning Date
- ADIL 11-12-2025
- SNOA 11-06-2025
- Dividend Yield
- ADIL N/A
- SNOA N/A
- EPS Growth
- ADIL N/A
- SNOA N/A
- EPS
- ADIL N/A
- SNOA N/A
- Revenue
- ADIL N/A
- SNOA $14,912,000.00
- Revenue This Year
- ADIL N/A
- SNOA $23.00
- Revenue Next Year
- ADIL N/A
- SNOA $24.59
- P/E Ratio
- ADIL N/A
- SNOA N/A
- Revenue Growth
- ADIL N/A
- SNOA 17.43
- 52 Week Low
- ADIL $0.22
- SNOA $1.75
- 52 Week High
- ADIL $1.30
- SNOA $6.92
- Technical
- Relative Strength Index (RSI)
- ADIL 58.88
- SNOA 50.30
- Support Level
- ADIL $0.37
- SNOA $3.72
- Resistance Level
- ADIL $0.41
- SNOA $4.60
- Average True Range (ATR)
- ADIL 0.02
- SNOA 0.20
- MACD
- ADIL 0.01
- SNOA 0.01
- Stochastic Oscillator
- ADIL 75.00
- SNOA 51.83
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.